KUMC HICTR CTSA outline

Safety and Tolerability Trial of Arimoclomol for Sporadic Inclusion Body Myositis. Y. Wang, Neurology. Assess the safety and tolerability of arimoclomol as compared with placebo over four months of treatment in patient with Inclusion Body Myositis. Multisite Kansas and London. (Sponsor: CytRx) Azacitidine in newly diagnosed Acute myelogenous leukemia . S Kambhampati, KU Cancer Center. Evaluate ... ................
................